European Regulators Grant Conditional Approval for Pfizer's Xalkori; Abbott Begins Marketing ALK CDx
October 24, 2012
European Regulators Grant Conditional Approval for Pfizer's Xalkori; Abbott Begins Marketing ALK CDx
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- CHMP Recommends Conditional Marketing Authorization for Pfizer's Leukemia Drug
January 23, 2013 / Pharmacogenomics Reporter - FDA Official Says Personalized Medicine Regulation Taking Shape Following Zelboraf, Xalkori Success
February 1, 2012 / Pharmacogenomics Reporter - Pfizer and Collaborators Developing Next-Gen Sequencing Test for Crizotinib Resistance Mutations
March 27, 2013 / Pharmacogenomics Reporter - Early Data Convinces Some Oncologists to Treat ROS1-Positive NSCLC Patients with Xalkori
June 6, 2012 / Pharmacogenomics Reporter - Abbott Challenges 'Incorrect Assumptions' in Cost-Effectiveness Study of Xalkori PGx Testing
March 28, 2012 / Pharmacogenomics Reporter